Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study.

ABSTRACT:

Background

The influences of blood lipids and lipid-regulatory medications on the risk of bladder cancer have long been suspected, and previous findings remain controversial. We aimed to assess the causality between blood lipids or lipid-regulatory medications and bladder cancer susceptibility by means of a comprehensive Mendelian Randomization (MR) study.

Methods

Genetic proxies from genome-wide association studies (GWAS) of four blood lipid traits and lipid-lowering variants in genes encoding the targets of lipid-regulatory medications were employed. The largest ever GWAS data of blood lipids and bladder cancer involving up to 440,546 and 205,771 individuals of European ancestry were extracted from UK Biobank and FinnGen Project Round 6, respectively. A two-sample bidirect

SUBMITTER: Cheng Z 

PROVIDER: S-EPMC10768687 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature